We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA hit Biologique Recherche with a warning letter after observing multiple violations at its Paris facility, noting inadequate testing methods, quality control concerns and a lack of validation for manufacturing processes, among other issues. Read More
The firm also failed to control its computer systems to assure that changes in master production and control records could only be done by authorized staff. Read More
The FDA hit Surmasis Pharmaceutical of Des Moines, Iowa with a Form 483 after a February inspection revealed problems with laboratory records, computer systems and equipment inspections. Read More
Sponsors may be referred to the Office of New Drugs if the product is a biological product or if it is not eligible for submission or approval as an ANDA but may be suited for another pathway. Read More
Chinese API manufacturer Henan Lihua drew a warning from the FDA over serious testing violations, inaccurate records and drug quality failures at its facility in Anyang, Henan. Read More
The manufacturer relied on certificates of analysis from unqualified suppliers instead of testing the attributes of incoming raw materials used in manufacturing. Read More
The FDA hit Biologique Recherche with a warning letter after observing multiple violations at its Paris facility, noting inadequate testing methods, quality control concerns and a lack of validation for manufacturing processes, among other issues. Read More
The FDA cited Reliance Life Sciences for a long list of deficiencies observed during an inspection of the API manufacturer’s facility in Navi Mumbai in December. Read More
The FDA hit Eau Zone Huiles Et Fragrances with a Form 483 after an inspection determined the OTC manufacturer had numerous deficiencies at its Montreal, Quebec facility, including cleaning, testing and drug storage issues. Read More
For products placed on the market as of the UK’s withdrawal date, batch release cannot be carried out by a laboratory located in the UK, the agency said. Read More